Key result
Losartan reduces urinary albumin excretion ~28% versus amlodipine in hypertensive non-diabetic nephropathy.
Why the study?
The effects of losartan versus amlodipine on proteinuria and renal function in hypertensive patients with non-diabetic nephropathy were not well characterized.
Does losartan compared to amlodipine reduce proteinuria and improve renal hemodynamics in hypertensive patients with non-diabetic nephropathy?
Comparison
Losartan versus amlodipine
Design
Prospective double-blind placebo-controlled randomized crossover trial
Follow-up
4 weeks per treatment period
Authors
Loading...
Losartan reduces proteinuria where amlodipine does not despite equivalent BP control; confirms ARB-specific renoprotection in non-diabetic nephropathy.
RCT (n=15)
Double-blind
Randomized crossover
Does losartan compared to amlodipine reduce proteinuria and improve renal hemodynamics in hypertensive patients with non-diabetic nephropathy?
Absolute Event Rate: 2684% vs 3748%
p-value: p=<0.01
Losartan, but not amlodipine, significantly reduces urinary albumin excretion and filtration fraction in hypertensive patients with non-diabetic nephropathy, despite comparable blood pressure lowering.
Holdaas et al. (1998) conducted an RCT in Hypertension with non-diabetic nephropathy (n=15). Losartan vs. Amlodipine was evaluated on Urinary albumin excretion (p=<0.01). Losartan significantly decreased urinary albumin excretion to 2684 mg/24 h (P<0.01), whereas amlodipine did not (3748 mg/24 h), in hypertensive patients with non-diabetic nephropathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: